Refractory Primary Mediastinal B-Cell Lymphoma: A Case Report of Conventional Chemotherapies, Immune Checkpoint Inhibitors, Polatuzumab Vedotin, Transplantation, and Post-Transplant Large Granular Lymphocytosis
Open Access
- 28 July 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 43 (06) , 523-527
Abstract
We report a case of stage IV primary mediastinal B-cell lymphoma in a 27-year-old young woman, who was refractory and chemoresistant to frontline conventional rituximab-based intensive chemotherapy and subsequent lines of conventional and immune checkpoint inhibitor-based therapies. She was successfully treated using a polatuzumab-based regimen and consolidated with an allogeneic haploidentical hematopoietic stem cell transplantation. She developed post-transplant large granular lymphocytosis that was managed conservatively. She is now relapse-free, 600 days post-transplant. The management of this patient provided several teaching points in the use of different modalities of immunotherapies in a hard-to-treat cancer and its related conditions.Keywords
This publication has 18 references indexed in Scilit:
- Large Granular Lymphocytosis after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort StudyTransplantation and Cellular Therapy, 2019
- Biology and therapy of primary mediastinal B‐cell lymphoma: current status and future directionsBritish Journal of Haematology, 2019
- The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice PaperBritish Journal of Haematology, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Diffuse Large B-Cell Lymphoma2018
- Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to TransplantTransplantation and Cellular Therapy, 2018
- How I treat primary mediastinal B-cell lymphomaBlood, 2018
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyThe Lancet Oncology, 2015
- Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell LymphomaNew England Journal of Medicine, 2013